Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
193
datasets available to search
ShareScore release 0.9.0
Dataset results
193 results for “CD20”
X-ray diffraction images of Anti-CD20 crystals
<p>Original X-ray diffraction images from Pilatus detector taken at Diamond Light Source Synchrotron (I04 beamline).</p> <p>Images can be read by AXDV (or similar) software.</p> <p>These datasets were used for diffraction and crystallographic analyses reported in Yang et al., Crystals 2019, 9, 230.</p> <p> </p>
A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma
ClinicalTrials.gov study NCT04074330. IPD Sharing: YES. Countries: 9. Publications: 1.
HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab
ClinicalTrials.gov study NCT00394836. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis
ClinicalTrials.gov study NCT02296775. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies
ClinicalTrials.gov study NCT02290951. IPD Sharing: YES. Countries: 5. Publications: 3.
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
ClinicalTrials.gov study NCT02900976. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)
ClinicalTrials.gov study NCT00517530. IPD Sharing: Not stated. Countries: 2. Publications: 6.
A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2
ClinicalTrials.gov study NCT01724021. IPD Sharing: Not stated. Countries: 32. Publications: 2.
A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma
ClinicalTrials.gov study NCT01649856. IPD Sharing: Not stated. Countries: 27. Publications: 1.
Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lym
ClinicalTrials.gov study NCT02951156. IPD Sharing: YES. Countries: 8. Publications: 1.
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B
ClinicalTrials.gov study NCT03277729. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
ClinicalTrials.gov study NCT01287741. IPD Sharing: Not stated. Countries: 29. Publications: 14.
Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients
ClinicalTrials.gov study NCT00494780. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
ClinicalTrials.gov study NCT02213263. IPD Sharing: YES. Countries: 30. Publications: 2.
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
ClinicalTrials.gov study NCT00001337. IPD Sharing: YES. Countries: 1. Publications: 10.
A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma
ClinicalTrials.gov study NCT01609010. IPD Sharing: Not stated. Countries: 3. Publications: 1.
A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease
ClinicalTrials.gov study NCT01680991. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell
ClinicalTrials.gov study NCT01088048. IPD Sharing: YES. Countries: 1. Publications: 3.
Decoding the molecular interplay of endogenous CD20 and therapeutic antibodies with fast volumetric nanoscopy
Open the record for dataset details and reuse information.
the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)
ClinicalTrials.gov study NCT02737085. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.